160 related articles for article (PubMed ID: 2758415)
21. Imbalance in the nucleotide pools of myeloid leukemia cells and HL-60 cells: correlation with cell-cycle phase, proliferation, differentiation, and transformation.
de Korte D; Haverkort WA; de Boer M; van Gennip AH; Roos D
Cancer Res; 1987 Apr; 47(7):1841-7. PubMed ID: 3469022
[TBL] [Abstract][Full Text] [Related]
22. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
23. Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line.
Lucas DL; Webster HK; Wright DG
J Clin Invest; 1983 Dec; 72(6):1889-900. PubMed ID: 6139386
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HKSV28 cell growth by 5,11-methenyl-tetrahydrohomofolate.
Slieker LJ; Benkovic SJ
Mol Pharmacol; 1984 Mar; 25(2):294-302. PubMed ID: 6700575
[TBL] [Abstract][Full Text] [Related]
25. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Habeck LL; Leitner TA; Shackelford KA; Gossett LS; Schultz RM; Andis SL; Shih C; Grindey GB; Mendelsohn LG
Cancer Res; 1994 Feb; 54(4):1021-6. PubMed ID: 8313357
[TBL] [Abstract][Full Text] [Related]
26. Cell cycle events associated with the termination of proliferation by cytotoxic and differentiation-inducing actions of 6-thioguanine on HL-60 cells.
Schwartz EL; Blair OC; Sartorelli AC
Cancer Res; 1984 Sep; 44(9):3907-10. PubMed ID: 6589046
[TBL] [Abstract][Full Text] [Related]
27. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
Chong LK; Tattersall MH
Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
[TBL] [Abstract][Full Text] [Related]
28. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
Erba E; Sen S; Sessa C; Vikhanskaya FL; D'Incalci M
Br J Cancer; 1994 Feb; 69(2):205-11. PubMed ID: 8297715
[TBL] [Abstract][Full Text] [Related]
30. Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells.
Lyons SD; Christopherson RI
Biochem Int; 1991 May; 24(1):187-97. PubMed ID: 1768258
[TBL] [Abstract][Full Text] [Related]
31. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
32. Effects of guanine ribonucleotide accumulation on the metabolism and cell cycle of human lymphoid cells.
Sidi Y; Hudson JL; Mitchell BS
Cancer Res; 1985 Oct; 45(10):4940-5. PubMed ID: 2411392
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase.
Piper JR; McCaleb GS; Montgomery JA; Kisliuk RL; Gaumont Y; Thorndike J; Sirotnak FM
J Med Chem; 1988 Nov; 31(11):2164-9. PubMed ID: 3184124
[TBL] [Abstract][Full Text] [Related]
34. A decrease in the intracellular guanosine 5'-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of Ras, the transforming principle of HL-60 cells.
Pilz RB; Huvar I; Scheele JS; Van den Berghe G; Boss GR
Cell Growth Differ; 1997 Jan; 8(1):53-9. PubMed ID: 8993834
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
36. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells.
Madlener S; Illmer C; Horvath Z; Saiko P; Losert A; Herbacek I; Grusch M; Elford HL; Krupitza G; Bernhaus A; Fritzer-Szekeres M; Szekeres T
Cancer Lett; 2007 Jan; 245(1-2):156-62. PubMed ID: 16488533
[TBL] [Abstract][Full Text] [Related]
37. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
38. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of folic acid enhancement of antifolate synergism.
Gaumont Y; Kisliuk RL; Parsons JC; Greco WR
Cancer Res; 1992 Apr; 52(8):2228-35. PubMed ID: 1532766
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells.
Dipietrantonio A; Hsieh TC; Wu JM
Biochem Biophys Res Commun; 1996 Jul; 224(3):837-42. PubMed ID: 8713132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
